The injectable gross margin that appears in QuickBooks for most medical spas is not the real number. It reads 80 to 90 percent because Allergan, Galderma, and Merz invoices are recorded in a separate accounts payable workflow and never reconciled against the service revenue they generated. The actual gross margin on neurotoxins and fillers, after subtracting vendor product costs, is 60 to 70 percent for a well-run practice. That 20-point gap is the difference between knowing your pricing and procurement decisions are sound and flying blind on the most important service line in your practice.
This article walks through the exact calculation, a worked Botox example, and the specific QuickBooks setup that makes the number reproducible every week without manual effort.
What is injectable gross margin? Injectable gross margin is the percentage of injectable service revenue that remains after subtracting the vendor product cost (Allergan, Galderma, Merz, Evolus) for the units used. The formula: (injectable revenue minus vendor COGS) divided by injectable revenue, times 100. A properly reconciled practice runs 60 to 70 percent. A practice whose QuickBooks shows 85 percent or higher is almost certainly missing vendor invoices in the COGS line, not outperforming the benchmark.
Why most med spa owners do not know their real injectable margin
The problem is structural, not intentional. Injectable revenue flows through your booking system, Zenoti, AestheticsPro, Boulevard, or PatientNow. It records every Botox treatment at $350, every filler syringe at $700, and totals them at month end into a service revenue figure.
Your injectable product costs flow through a completely different channel. Allergan invoices arrive by email from Brilliant Distinctions or your Allergan representative.
Galderma invoices come through the Galderma portal or your distributor. Merz, Evolus, and Revance have their own ordering systems. Each of these invoices ends up in accounts payable as a purchase, coded to whatever expense account your bookkeeper assigned, usually Medical Supplies or General Supplies, and it sits there, disconnected from the revenue it generated.
In most QuickBooks setups, these two data streams have never been linked. The result: your injectable service line shows 85 percent gross margin because the cost side is invisible. That inflated number affects every downstream decision, whether to lower pricing to compete, whether to pursue a higher-volume Allergan rebate tier, whether to hire another injector.
How to calculate injectable gross margin: the step-by-step process
- 1Pull total injectable service revenue from your booking system. Use Zenoti, AestheticsPro, Boulevard, or PatientNow, not QuickBooks, as your source for this number. Filter for neurotoxins (Botox, Dysport, Xeomin, Daxxify) and fillers (Juvederm, Restylane, Sculptra, Radiesse, RHA) separately if you want service-line detail. Get the gross revenue figure for the period.
- 2Pull all vendor invoices for the same period. Collect every Allergan, Galderma, Merz, Evolus, and Revance invoice paid or received during the same period. This is your injectable COGS. Total them. If invoices are in multiple places (email, vendor portals, accounts payable), gather them all. Missing one vendor skews the calculation.
- 3Calculate gross margin. The formula: (Injectable Revenue minus Injectable COGS) divided by Injectable Revenue, multiplied by 100. If revenue was $45,000 and COGS was $14,850, the calculation is ($45,000 minus $14,850) divided by $45,000, times 100 = 67 percent gross margin.
- 4Compare against the 60 to 70 percent benchmark. Below 55 percent indicates a pricing, waste, or vendor cost problem. Above 75 percent means vendor invoices are probably incomplete. The apparent high margin is missing cost, not actual strong performance.
- 5Code vendor invoices to an Injectable COGS account in QuickBooks. Create a COGS account named "Injectable COGS" under Cost of Goods Sold. Code every vendor invoice to this account going forward. This is what makes the gross margin calculation reproducible from QuickBooks without a manual reconciliation every month.
Common mistake: trusting the 85%+ injectable margin on the QuickBooks P&L
When a practice's injectable service line shows 85 or 90 percent gross margin month after month, the instinct is to treat it as a pricing win. It is almost always a data gap. Vendor invoices are living in email and the Allergan portal, not in the COGS column. The practice is running 60 to 70 percent real margin with 20 to 30 points of phantom profit on the books. Every pricing, rebate, and staffing decision made off the inflated number is made on fiction. Run a three-month vendor invoice reconciliation before concluding the margin is real.
Worked example: Botox gross margin calculation
Take a single-injector practice with the following monthly figures:
Without reconciling the vendor invoices, this practice's QuickBooks would show $50,660 in injectable revenue against $0 in specific injectable COGS, effectively an 100 percent gross margin on injectables. With the invoices coded correctly, the real number is 71.1 percent.
That is still a healthy margin, but the gap between the apparent number and the real number is 29 percentage points. Pricing decisions, staffing decisions, and service-line growth decisions made on the inflated figure are made on inaccurate information.
How neurotoxin pricing affects your margin per treatment
At the treatment level, the math looks like this for a standard forehead and frown line Botox treatment:
| Treatment price | Units used | Product cost (at $6.20/unit) | Gross margin |
|---|---|---|---|
| $450 | 40 units | $248 | 44.9% |
| $550 | 40 units | $248 | 54.9% |
| $650 | 40 units | $248 | 61.8% |
| $550 | 50 units | $310 | 43.6% |
| $650 | 50 units | $310 | 52.3% |
Per-unit Allergan pricing at $6.20 assumes standard-tier Brilliant Distinctions pricing. Your actual cost per unit will vary based on your purchase volume and rebate tier. Higher volume unlocks lower per-unit cost, which is one of the core reasons tracking actual unit volume weekly matters, it tells you whether you are approaching a more favorable rebate threshold.
The owners who do not flinch on Botox pricing already know their cost per unit after the Allergan invoice. The number removes the guesswork from the pricing conversation.
What the injectable margin tells you about your practice
A margin consistently above 70 percent indicates one of three things: strong pricing, favorable vendor rebate tiers, or (most commonly) vendor invoices are not fully captured. Run a three-month reconciliation to confirm which it is before concluding the margin is genuinely strong.
A margin consistently below 55 percent points to one of four problems:
- Pricing below market: Per-treatment revenue is too low relative to product cost. Recalculate your pricing using the per-unit cost formula above.
- High waste: Vials are not being fully utilized. Units disposed rather than used are pure cost with no revenue. Track dispensed units versus billed units weekly.
- Unfavorable vendor tier: Low purchase volume means higher per-unit pricing. Evaluate whether consolidating purchases to a single vendor improves your rebate tier and unit economics.
- Incorrect COGS capture: Some vendor invoices are being missed. Run a reconciliation against all vendor portal histories to verify completeness.
None of these diagnoses are visible if injectable COGS are sitting in a General Supplies account. They only surface once vendor invoices are coded correctly to an Injectable COGS line and reconciled against the service revenue they generated. That reconciliation is the starting point. Everything downstream depends on it.
See your real injectable margin in 48 hours.
Spa Ledger reconciles Allergan, Galderma, and all injectable vendor invoices against service revenue each week. Your first report shows the real gross margin by neurotoxin and filler, most clients see it for the first time. First month free, no card required.
Reserve Your First Month